Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually ...

McNamara’s Fallacy is the error of making decisions based solely on easily quantifiable data, while ignoring ...

Sanofi has announced that its Rezurock (belumosudil) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the ...

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — ...

Johnson & Johnson has announced that its Darzalex Faspro-based regimen (daratumumab and hyaluronidase, in combination with ...

Alzheimer’s disease (AD) continues to be one of the most challenging conditions facing patients, families and healthcare ...

Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...

Skyhawk Therapeutics has announced positive interim results from its phase 1 trial of SKY-0515, an investigational treatment ...

The current landscape The landscape of dementia clinical trials in Europe is focused on AD, the most common form of dementia.

Boehringer Ingelheim and Simcere have announced a new license and collaboration agreement for the development of SIM0709, a ...

AstraZeneca and CSPC Pharmaceuticals have announced a new collaboration agreement for the development of therapies for obesity and type 2 diabetes.

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...